Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2017 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for evidence in the transcript. The transcript covers Q2 2017 earnings call. Management discusses various aspects: MS franchise, SPINRAZA launch, biosimilars, pipeline, business development, etc. Key points: - They mention "value-based contracting" with four agreements executed in July. They describe two approaches: aligning price to patient outcomes, and adjusting price for patients initiating therapy who discontinue. They call these pilots. They say "We believe this pilot will provide valuable information that we can apply to future contracting approaches." This is about contracting, but it's not about size of deals; it's about pricing models. Not about larger deals. - They mention business development: they acquired Remedy Pharmaceuticals' asset, and licensed BIIB092 from BMS. These are acquisitions, not repeatable business engagements. They are one-off deals. - They talk about SPINRAZA launch: they mention increasing sites, coverage, etc. But that's about volume, not size of individual engagements. - They talk about biosimilars: revenues growing, but not about individual deal size. - They talk about pipeline: they aim to grow late-stage pipeline from two assets to substantially more by 2021. That's about number of assets, not size of each. - They talk about capital allocation: they prioritize business development, but no mention of increasing deal sizes. - They talk about "lean and simple operating model" to free up $400 million annually to reinvest. That's about cost savings, not deal size. - They mention "we are actively reallocating resources to high-priority R&D BD and commercial growth opportunities." No specific mention of larger deals. - They mention "we aim to do much more business development" but no mention of larger individual deals.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.